Login to Your Account



Other News To Note


Tuesday, December 6, 2011

• DiaMedica Inc., of Winnipeg, Manitoba, reported results of a preclinical study in Type I diabetes showing that chronic administration of lead compound DM-199 delayed the autoimmune attack, preserved beta cell mass and demonstrated a 12-fold increase in circulating C-peptide levels – the primary endpoint in most Type I diabetes trials – in the non-obese diabetic animal model. The increase in C-peptide levels reflected improved insulin secretion and suggested the ability of DM-199 to stabilize and preserve C-peptide in peripheral blood, according to the company.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription